En español
NIDA

Menu

NIDA Notes Articles: Medication Development

NIDA Notes Category Graphic

NIDA Announces Avant-Garde Medication Development Awards

March 2012
Dr. Thomas Kosten of Baylor College of Medicine and Dr. Peter Burkhard of the University of Connecticut are the recipients of NIDA’s 2011 Avant-Garde Awards for Innovative Medication Development Research. Dr. Kosten is developing a vaccine against methamphetamine abuse and Dr. Burkhard is developing a vaccine to counter nicotine addiction.

NIDA Notes Category Graphic

New Vaccines Are Being Developed Against Addiction and Relapse

December 2008

Highlights NIDA-funded research to develop vaccines against addiction to drugs such as cocaine, nicotine, phencyclidine (PCP), and methamphetamine.

NIDA Notes Category Graphic

New Tools and Strategies to Bolster Behavioral Therapy

October 2010

Reports on research investigating whether certain medications might strengthen patients' understanding and memory retention.

NIDA Notes Category Graphic

Neuropeptide Promotes Behaviors Tied to Addiction and Overeating

July 2011

Reports on several studies implicating a certain neuropeptide (a signaling molecule) in fostering addition and overeating and discusses implications for addiction treatment.

NIDA Notes Category Graphic

Naltrexone-Nicotine Patch Combination Shows Promise

April 2007
Reports findings from a clinical trial investigating the effectiveness of naltrexone as a supplement to nicotine replacement therapy for smoking cessation.

NIDA Notes Category Graphic

Naltrexone via Skin Patch Proves Effectiveness of New Technology

November 2009

Reports on a new device that creates tiny painless punctures in the skin to allow medication to flow evenly from a skin patch into dermal capillaries and the bloodstream.

NIDA Notes Category Graphic

Naltrexone Implant Outperforms Daily Pill in Russian Trial

November 2013

More than half of heroin-addicted patients treated with naltrexone via an implanted delivery device maintained abstinence throughout a 6-month clinical trial in Saint Petersburg, Russia. The implant device, which releases a steady dose of naltrexone continuously for 2 months, averted relapse to heroin use three times as effectively as daily oral doses of the medication.

NIDA Notes Category Graphic

N-Acetylcysteine Postsynaptic Effect Limits Efficacy

January 2013

Clinical trials of N-acetylcysteine to help people recovering from drug abuse avoid relapse have demonstrated only moderate efficacy. New NIDA-supported research shows that while a low dose of the medication activates receptors associated with lowered drug-seeking behavior, a higher dose appears to activate receptors associated with increased drug-seeking behavior. The result suggests that a medication or combination of medications that stimulate the receptor GluR2/3 and block mGluR5 may work better than N-acetylcysteine alone.

NIDA Notes Category Graphic

More Convenient Preparations of Buprenorphine Pass Test

July 2012

Soluble-film preparations of buprenorphine suppressed heroin abusers’ withdrawal symptoms with no serious side effects in a recent clinical trial. They dissolved more rapidly in the mouth than the pill form of the medication, providing faster relief.

NIDA Notes Category Graphic

Modafinil Normalizes Sleep During Early Cocaine Abstinence

December 2010
Describes a study investigating the effectiveness of modafinil in enhancing sleep among cocaine abusers who are currently abstinent.

Pages

NIDA Notes

Tags

Drug Topics

Drugs of Abuse

Population Groups

Related Topics